William Blair & Company’s Sierra Oncology, Inc. Common Stock SRRA Stock Holding History

William Blair & Company’s Portfolio SRRA Stock Details SRRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	–	Sell	-423	Closed	-$7K	–	1818
2019 Q3	$7K	Sell	423 -310	-42%	-$5.93K	﹤0.01%	1629
2019 Q2	$16K	Hold	733	–	–	﹤0.01%	1607
2019 Q1	$50K	Buy	733 +310	+73%	+$19.9K	﹤0.01%	1465
2018 Q4	$22K	Hold	423	–	–	﹤0.01%	1480
2018 Q3	$29K	Sell	423 -970	-70%	-$88K	﹤0.01%	1505
2018 Q2	$165K	Hold	1,393	–	–	﹤0.01%	1292
2018 Q1	$115K	Buy	1,393 +244	+21%	+$27.7K	﹤0.01%	1256
2017 Q4	$171K	Hold	1,149	–	–	﹤0.01%	1280
2017 Q3	$71K	Hold	1,149	–	–	﹤0.01%	1319
2017 Q2	$54K	Hold	1,149	–	–	﹤0.01%	1465
2017 Q1	$70K	Hold	1,149	–	–	﹤0.01%	1314
2016 Q4	$68K	Buy	1,149 +689	+150%	+$43K	﹤0.01%	1244
2016 Q3	$33K	Buy	460 +43	+10%	+$3.32K	﹤0.01%	1261
2016 Q2	$33K	Buy	+417	New	+$79.5K	﹤0.01%	1204

Other funds holding SRRA

NLVP

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hikari Power Tokyo, Japan $1.15B AUM 5.31% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

Greenleaf Trust Kalamazoo, Michigan $10.4B AUM 0.97% 1-Year Est. Return

William Blair & Company's SRRA Position: Q4 2019 in Review

William Blair & Company sold out of Sierra Oncology, Inc. Common Stock (SRRA) in Q4 2019, closing a stake of 423 shares — an estimated $7K sold.

William Blair & Company first reported a position in SRRA in Q2 2016 and held it in 14 quarters. The position peaked at $171K in Q4 2017. 29 funds tracked by Wall St. Rank hold SRRA as of Q4 2019.

William Blair & Company reported no remaining Sierra Oncology, Inc. Common Stock position as of Q4 2019 after selling out during the quarter.
William Blair & Company sold 423 Sierra Oncology, Inc. Common Stock shares in Q4 2019, an estimated $7K.
William Blair & Company first reported a position in Sierra Oncology, Inc. Common Stock in Q2 2016 and held it in 14 quarters.
William Blair & Company's Sierra Oncology, Inc. Common Stock position peaked at $171K in Q4 2017.
29 funds tracked by Wall St. Rank held Sierra Oncology, Inc. Common Stock as of Q4 2019.

Based on William Blair & Company's 13F filing for Q4 2019, filed 13 Feb 2020.